Clinical role of technetium-99m sestamibi single-photon emission tomography in evaluating pretreated patients with brain tumours

Lorenzo Maffioli, Massimo Gasparini, Arturo Chiti, Alberto Gramaglia, Valeria Mongioj, Annalisa Pozzi, Emilio Bombardieri

Research output: Contribution to journalArticlepeer-review

Abstract

One of the main problems regarding the follow-up of patients with brain tumours treated with radiotherapy is the distinction between radiation necrosis and tumour relapse. In many cases computed tomography (CT) scan is unable to distinguish between the two. We assessed the usefulness of brain single-photon emission tomography (SPET) with technetium-99m-sestamibi in cases where CT scan was not conclusive. The absence of tracer uptake in normal brain, the sharp uptake in neoplastic tissue, and the favourable physical properties of technetium make the scintigraphic method particularly accurate. We therefore propose the association of CT scan with 99mTc-sestamibi brain SPET in the follow-up of patients in whom a distinction between radiation necrosis and active disease is needed for an adequate therapeutic decision.

Original languageEnglish
Pages (from-to)308-311
Number of pages4
JournalEuropean Journal Of Nuclear Medicine
Volume23
Issue number3
DOIs
Publication statusPublished - 1996

Keywords

  • Brain tumour
  • Radiation necrosis
  • Relapse
  • Sestamibi

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Clinical role of technetium-99m sestamibi single-photon emission tomography in evaluating pretreated patients with brain tumours'. Together they form a unique fingerprint.

Cite this